Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115, ...

We recently published a list of These 10 Companies Led Tuesday’s Charge. In this article, we are going to take a look at ...

Elizabeth E. Reed, Senior Vice President, General Counsel, and Corporate Secretary of Travere Therapeutics, Inc. (NASDAQ:TVTX), reported selling 8,000 shares of the company's common stock. The sale, ...

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Travere Therapeutics (TVTX – Research Report), with a ...

Scotiabank analyst Greg Harrison raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $27 and keeps an Outperform rating ...

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...